Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAESTRO-NASH OUTCOMES
2022-002279-13Phase 3Active
- Sponsor
- Madrigal Pharmaceuticals
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cirrhosis due to nonalcoholic steatohepatitis comparing Resmetirom with Placebo (2 arms). Primary endpoint: Time to first confirmed adjudicated composite clinical outcome event. Started Jan 2023; status: active.
02
Drugs
resmetirom
03
Conditions
cirrhosis due to nonalcoholic steatohepatitis
Beyond the preview
Go deeper on 2022-002279-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002279-13.